Navigation Links
Many Heart Attack Patients Don't Get Best Emergency Treatment
Date:8/19/2007

ANN ARBOR, Mich., Aug. 3 /PRNewswire-USNewswire/ -- Far more of today's heart attack patients receive emergency angioplasty treatment or clot-busting drugs to re-open their clogged heart arteries than even a decade ago, a new study finds.

But 10 percent of patients who could benefit from this urgent treatment -- which is known to save lives and prevent lasting damage to the heart muscle -- don't get it at all, the study shows.

And the chance of missing out on lifesaving emergency treatment was highest among those patients whose heart attack symptoms don't include typical symptoms like chest pain, those who didn't reach the hospital until six or more hours after the start of their attack, women, people over age 75, and non-white people.

The study, published in the American Journal of Medicine by a team led by cardiologists from the University of Michigan Cardiovascular Center and the Yale University School of Medicine, is based on data from 238,291 patients who had had a type of heart attack for which this therapy is appropriate between 1994 and 2003.

It's the most current and comprehensive look at the use of emergency "reperfusion" -- a term that describes treatments that can break up blood clots and other blockages in the tiny blood vessels of the heart and restore blood flow to the heart muscle.

In the ten-year study period, the percentage of patients who could have received emergency reperfusion but didn't declined from more than 20 percent to 10 percent - a notable achievement that the authors attribute to the increasing evidence of the benefit of emergency angioplasty, and the rise in the availability of the treatment at American hospitals and concerted national efforts to improve care.

The database used for the study, called the National Registry of Myocardial Infarction, includes detailed information about each patient's condition that can be used to determine if they would meet the criteria to receive emergency angi
'/>"/>

SOURCE University of Michigan Health System

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... -- Packaging Coordinators, Inc. (PCI) is pleased to announce it ... Services Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... United Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug ... form manufacturing, as well as Clinical Packaging, Labeling, and ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... imaging,(BSGI) is effective in the detection of cancers not ... study presented today at the annual meeting of,the Radiological ... "BSGI can identify the most difficult ... F. Brem, M.D., professor of,radiology and director of the ...
... Horizon Therapeutics, Inc., a,privately held biopharmaceutical ... 3 trials evaluating its lead investigational ... HZT-501, a novel, proprietary fixed-dose,combination product ... significant reduction in the incidence of ...
Cached Medicine Technology:New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- For patients ... is enough to trigger airway inflammation for at least ... just what you smell, but also what you think ... Monell Chemical Senses Center in Philadelphia, said in a ... about scents and fragrances. When we expect that an ...
(Date:7/30/2014)... jockeying for supremacy within a cancerous tumor, the most ... fastest, researchers at Dana-Farber Cancer Institute report in a ... journal Nature . The findings have important ... the study authors explained: Doctors need to ascertain which ... metastasis and select drugs that target the critical genes ...
(Date:7/30/2014)... 2014 On July 29, 2014, Freedom ... Institute of Public Health, Gandhinagar released a new report ... II: The Way Forward .” The report was released ... and Practices to Improve Nutrition Security in New Delhi, ... the Green Revolution" and chair of the Coalition ...
(Date:7/30/2014)... 2014 Shabaikai is an ambitious historical ... the Pomo Indians located on the shores of Russian ... Shabaikai, meaning ‘crooked snake’. Clarkson takes the reader into ... violence of prohibition and organized crime, providing a glimpse ... the most powerful men in the world convene the ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 With the recent ... Ground Zero, the Ground Zero Museum Workshop in the Meatpacking ... bookings. Says the Museum Workshop's Carole Barnes, "We have had ... all the major travel sites who sell us so tourists ... crystal clear as to what we do and what the ...
Breaking Medicine News(10 mins):Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5
... the second day of Sedation Dentistry Safety Week, the spotlight ... team members throughout the United States who help ensure that ... comfortable and anxiety-free. "Safety is very much an all-team responsibility," ... and one of the world,s leading sedation dentistry educators. ...
... the reader,s choice award for Westlake village and East Ventura County in ... caring local business represented in the newspaper. , ... Westlake Village, CA ... Khanna the reader,s choice award for Westlake village and East Ventura ...
... Diamond Mothers Day Card for Breast Cancer Campaign,Hallmark Cards ... designed by Strictly Come Dancing host, Tess Daly, to support its ... donate £1/4 million to two breast cancer charities. , ... ...
... given financial incentives to improve the quality of ... of changes important to advancing quality, according to ... adopted by medical groups include speeding up adoption ... more closely tracking the improvement of physician performance ...
... Invention Machine , a leading provider of ... by Blue Highway LLC to help transform ... in medical diagnostics. A Welch Allyn company, ... software to accelerate and sustain product innovation, deliver ...
... MOUNTAIN VIEW, Calif., March 9 Alexza Pharmaceuticals, Inc. ... corporate presentation will be webcast live during the Cowen ... 17, 2008 at 4:40 p.m. Eastern Time. The ... Place. To access the live presentation via the ...
Cached Medicine News:Health News:Sedation Dentistry Safety Week Spotlights the Important Role of Dental Team Members 2Health News:Sedation Dentistry Safety Week Spotlights the Important Role of Dental Team Members 3Health News:Ventura County Star Newspaper Honors Khanna Institute 2Health News:Tess Daly Supports Hallmark's Breast Cancer Campaign 2Health News:Tess Daly Supports Hallmark's Breast Cancer Campaign 3Health News:Study finds pay for performance stimulates changes in medical practice 2Health News:Study finds pay for performance stimulates changes in medical practice 3Health News:Blue Highway Selects Invention Machine Goldfire to Fuel Product Pipeline and Sustain Breakthrough Innovation 2Health News:Blue Highway Selects Invention Machine Goldfire to Fuel Product Pipeline and Sustain Breakthrough Innovation 3Health News:Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference 2Health News:Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference 3
... Focus multichannel pipettes speed ... reagents into microplates, with ... l volumes. The improved ... Focus multichannels, combined with ...
... rows, and microplatesthat is the area of ... becoming an ever-increasing force. Ergonomics (reduced weight ... reason that the Multichannel Research model was ... provides effective, precise, and rapid processing of ...
... Hall, the aortic and mitral valves are distinctly ... the disc opens to 75 to maximize forward ... to minimize regurgitation. Designed to rotate within its ... the leading edge of the disc parallel to ...
Inquire...
Medicine Products: